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While IL-12 plays a key role in differentiation of protective CD4+ Th1 response,
little is known about mechanisms whereby IL-12 differentiates other T-cell
populations. Published studies suggest that predominant Vγ2Vδ2T cells in
humans/nonhuman primates (NHP) are a fast-acting T-cell subset, with capacities
to rapidly expand and produce Th1 and cytotoxic cytokines in response to
phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) produced
by Mycobacterium tuberculosis (Mtb) or others. However, whether IL-12 signaling
pathway mediates fast-acting and Th1 or anti-microbial features of Vγ2Vδ2T cells
remains poorly defined. Here, we show that IL-12, but not other IL-12 family members
IL-27/IL-35, apparently expanded HMBPP-activated Vγ2Vδ2T cells. Although IL-12
and IL-2 similarly expanded HMBPP-activated Vγ2Vδ2 T-cell clones, the IL-12-induced
expansion did not require endogenous IL-2 or IL-2 co-signaling during HMBPP +
IL-12 co-treatment. IL-12-induced expansion of Vγ2Vδ2T cells required the PI3K/AKT
and STAT4 activation pathways and endogenous TNF-α signaling but did not involve
p38/MAPK or IFN-γ signals. IL-12-expanded Vγ2Vδ2 T cells exhibited central/effector
memory phenotypes and differentiated into polyfunctional effector cell subtypes which
expressed TBX21/T-bet, antimicrobial cytokines IFN-γ, TNF-α, GM-CSF, and cytotoxic
granule molecules. Furthermore, the IL-12-expanded Vγ2Vδ2T cells inhibited the growth
of intracellular mycobacteria in IFN-γ- or TNF-α-dependent fashion. Our findings support
the concept that IL-12 drives early development of fast-acting Vγ2Vδ2T effector cells in
antimicrobial immune responses.
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INTRODUCTION
Interleukin-12 (IL-12) is a critical cytokine produced by
monocytes/macrophages and dendritic cells in response to
microbial pathogens (1–3). IL-12 also plays an important role in
biological regulation of lymphocytes, as it can help to promote
T cells for Th1 differentiation (4), augment proliferation of
pre-activated T and NK cells (5), prompt the production of
IFN-γ (6), and enhance cytolytic activity of cytotoxic T and
NK cells (7). In fact, studies in humans and animals have
demonstrated that IL-12 is essential for in vivo IFN-γ production
and induction/maintenance of antigen-specific CD4+ Th1 cells
for development of protective immunity against intracellular
pathogens including resistance to Mycobacterium tuberculosis
(Mtb) infection (8, 9). However, little is known about whether
IL-12 can promote immune response or function of other T-
cell populations that do not express CD4 during Mtb or other
microbial infections.
γδ T cells appear to be a non-conventional T-cell population
that contributes to both innate and adaptive immune responses
against microbial infections (10). Vγ2Vδ2 T-cell subpopulation
unique in humans and nonhuman primates (NHP) constitute
65–90% of total circulating human γδ T cells and remain the
sole γδ T-cell subset capable of recognizing phosphoantigens
such as the isopentenyl pyrophosphate (IPP) metabolite (11) and
(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP)
produced by Mtb and other microbes (12). Studies in humans
and NHP (13–17) have shown that IPP- or HMBPP-activated
Vγ2Vδ2 T cells can readily produce Th1 cytokines IFN-γ/TNF-
α and cytotoxic granule molecules perforin (PRF), granzyme
A/B (GZMA/B), and granulysin (GNLY), and consistently
exhibit antimicrobial and anti-cancer activities. On the other
hand, activated Vγ2Vδ2 T cells can be expanded by IL-2, IL-
7, IL-15, IL-21, IL-33, and Th17-related cytokines (13, 18–21).
Furthermore, recent seminal studies in NHP models suggest
that the phosphoantigen HMBPP-specific Vγ2Vδ2 T-cell subset
can respond as fast-acting T cells, undergo rapid expansion and
pulmonary trafficking and residence, and attenuate high-dose
Mtb infection (10, 15, 16). However, whether IL-12 signaling
pathway mediates fast-acting and Th1 or anti-microbial features
of Vγ2Vδ2 T cells remains poorly defined (22, 23).
In the current study, we performed mechanistic experiments
to test the hypothesis that IL-12, a key innate cytokine produced
by Mtb infection of macrophages/DC, plays a role in the early
development of fast-acting Vγ2Vδ2 T effector cells. Our study
provides previously-unreported data implicating signaling
pathways, cytokine networks and functional mechanisms
whereby IL-12 expands and differentiates HMBPP-activated
Vγ2Vδ2 T effector cells producing multiple anti-TB cytokines
and inhibiting mycobacterial growth.
MATERIALS AND METHODS
Expansion of Vγ2Vδ2T Cells by HMBPP
Plus Cytokines in PBMC Culture
The protocols for human blood samples for in vitro experimental
procedures were evaluated and approved by the institutional
review boards for human subjects’ research and institutional
biosafety committees at Shanghai Pulmonary Hospital. All
subjects are adults and signed written informed consents. Human
PBMCwere isolated from collected fresh blood of healthy donors
by density gradient centrifugation using Ficoll-Paque PLUS (GE)
as described (16, 24). For expansion assay, 0.5 million PBMCs
were cultured in the absence or presence of 10 ng/mL of HMBPP
(provided by Dr. H. Jomaa, Germany), with/without 5 ng/mL
IL-2 (R&D) or 25 ng/mL IL-12 (Miltenyi Biotech) at 200 ul in
96-U-well plate. Fresh culture media (RPMI1640 + 10% FBS,
purchased from Life Technologies) with indicated cytokines was
added into cultures every 2–3 day. CD4- or CD8- depleted PBMC
were prepared from freshly PBMC by sorting CD4 or CD8T
cells out using MACS method (Miltenyi). In proliferation assays,
CD4-depleted, CD8-depleted or undeleted PBMCs were labeled
with 2µM CFSE (Life Technology), washed out, then cultured
with media, HMBPP, IL-12, or HMBPP + IL-12 for 7 days.
Cells were harvested at day 7, and the proliferation of Vγ2Vδ2 T
cells was analyzed by flow cytometry. In special assays, PBMCs
were co-cultured with HMBPP + IL-12 or HMBPP + IL-2
with or without TNF-α (Invitrogen) or TGF-β1 (Peprotech) at
indicated concentration. PBMCs were co-cultured with IL-2 or
IL-12 stimulated by plate-coated 1 ug/ml anti-CD3 Ab (OKT3,
BD) plus soluble 1 ug/ml anti-CD28 Ab (CD28.2, BD) or HMBPP
for 7 days. The following neutralization antibodies and their
corresponding isotype controls were used in antibody blocking
assays: anti-IL-2 (MQ1-17H12; BD), IgG (R35-95, BD); anti-IL-
2 (Polyclonal, AF219; R&D), IgG (Polyclonal, AB-108, R&D);
anti-IFN-γ (MD-1, Biolegend), anti-TNF-α (MAb1, Biolegend)
and IgG (MOPC-21, Biolegend). (+/–)-Lisofylline (LSF, ENZO)
was used for IL-12/STAT4 axis-targeted inhibiting experiments.
SB203580 and LY294002 purchased from Abmole, were used
for inhibiting p38-MAPK and PI3K/AKT pathway, respectively.
Inhibitors were used at indicated concentration and added along
with cytokines every 2–3 days during 7-day-culture.
Repertoire Analysis of Expanded Vγ2Vδ2
T Cells
Expanded Vγ2Vδ2 T cells from HMBPP + IL-12 or HMBPP +
IL-2 cultures were used for RNA isolation and re-transcribed into
cDNA library (25). Fragments containing Vγ2- and Vδ2-specific
CDR3 sequences were amplified by standard PCR kit (Yeasen),
using the following primers: 5′-ATCAACGCTGGCAGTCC-
3′ and 5′-AAGGAAGAAAAATAGTGGGC-3′ for Vγ2
chain; 5′-GCAGGAGTCATGTCAGCCAT-3′ and 5′-
GACAAGCGACATTTGTTCCA-3′ for Vδ2 chain (26). The
PCR fragments were purified from PCR system by PCR products
purification kit (Axygen), and then ligated into the pMD-19T
cloning vector (Takara). The recombinant plasmids were
transfected by heat shock into DH5α competent cells (Sanyou
Biotech). Colonies were picked and grown overnight in 4ml of
Luria-Bertani broth containing Ampicillin (50 mg/ml). Plasmids
were purified using the plasmid Miniprep kit (Axygen). The
sequences of plasmids were determined by Huagen Biotech.
CDR3 lengths and VDJ rearrangements were analyzed through
IMGT/V-QUEST (27).
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Characterizing Memory Surrogates and
Surface Markers on Expanded Vγ2Vδ2
T Cells
Cultured cells were washed with PBS, stained with Zombie
Fixable Viability Kit (Biolegend), followed by staining with
monoclonal Abs against special surface markers. For cell
memory state analysis, cells were incubated with PB-anti-
CD3 (SP34-2, BD), FITC-anti-Vγ2 (7A5, Thermo Scientific),
PE-anti-Vδ2 (B6, Biolegend), BV785-anti-CD45RA (HI100,
Biolegend), PE/Cy7-anti-CD27 (O323, Biolegend), PE/Cy5-anti-
CD28 (CD28.2, Biolegend) for 20min at room temperature
in dark. For phenotyping of special surface markers, cells
were incubated with PB-anti-CD3 (SP34-2, BD), FITC-anti-Vγ2
(7A5, Thermo Scientific), PE-anti-Vδ2 (B6, Biolegend), APC-
anti-CCR5 (J418F1, Biolegend), PE/Cy5.5-anti-LFA-1 (TS1/18,
Biolegend) for 20min at room temperature in dark. Then cells
were washed and fixed by fixing buffer (2% formalin in PBS),
analyzed on an LSR Fortessa flow cytometer (BD).
Intracellular Cytokine Staining (ICS) for
Functional Evaluation
PBMCs cultured for 7 days were firstly treated with/without
40 ng/ml HMBPP, pulsing PE/CF594-anti-CD107a (H4A3,
Biolegend), and BFA (GolgiPlug, BD) for 6 h. Then cells were
stained with Zombie Fixable Viability Kit (Biolegend), incubated
with PB-anti-CD3 (SP34-2, BD), FITC-anti-Vγ2 (7A5, Thermo
Scientific), PE-anti-Vδ2 (B6, Biolegend) for 20min at room
temperature in dark. Cells were permeabilized for 30min
at 4 degrees (Cytofix/Cytoperm, BD). After wash, cells were
incubated with BV711-anti-IFN-γ (4S.B3; Biolegend), PE/Cy7-
anti-TNF-α (Mab11, Biolegend), Percp/Cy5.5-anti-GM-CSF
(BVD2-21C11, Biolegend) for 30min at room temperature in
dark. Then cells were washed and analyzed on an LSR Fortessa
flow cytometer (BD). CD107a was used to assess degranulation
of cytotoxic molecules; IFN-γ, TNF-α, and GM-CSF was used to
evaluating anti-mycobacteria effector function. Flow data were
analyzed by FlowJo (TreeStar).
Quantification of Gene Expression in
Expanded Vγ2Vδ2 T Cells
RNA isolation from enriched and stimulated Vγ2Vδ2 T cells,
reverse-transcription and PCR reactions were done as described
in Qaqish et al. (16). Primers used for amplification were listed as
following and synthesized from Sangon Biotech: GNLY-F, 5′-G
TACTACGACCTGGCAAGAGCC-3′, GNLY-R, 5′-TCAGACA
GGTCCTGTAGTCACG-3′; PRF-F 5′-ACTCACAGGCAGCCA
ACTTTGC-3′, PRF-R, 5′-CTCTTGAAGTCAGGGTGCAGCG-
3′; GZMA-F 5′- CCACACGCGAAGGTGACCTTAA-3′, GZMA
-R, 5′-CCTGCAACTTGGCACATGGTTC-3’; GZMB -F, 5′- C
GACAGTACCATTGAGTTGTGCG-3′, GZMB -R, 5′-TTCGT
CCATAGGAGACAATGCCC-3′; TBX21-F, 5′-ATTGCCGTGA
CTGCCTACCAGA-3’,TBX21-R, 5′-GGAATTGACAGTTGGG
TCCAGG-3′; Foxp3-F, 5′- GGCACAATGTCTCCTCCAGAGA-
3’,Foxp3-R, 5′-CAGATGAAGCCTTGGTCAGTGC−3′; EF1A-F,
5′-GATTACAGGGACATCTCAGGCTG-3′, EF1A-R, 5′-TATC
TCTTCTGGCTGTAGGGTGG-3′. EF1A was used as a reference
gene. Fold change was calculated with the delta Ct method.
Intracellular Mycobacterial Growth
Inhibition Assay
Mycobacterium bovis Bacillus Calmette-Guerin (BCG)-infected
THP-1 and human monocytes-derived macrophages (hMDM)
were prepared as target cells atMOI 10 as we previously described
(24). Extracellular BCG were then washed out. To isolate or
purify Vγ2Vδ2+ T cells, cells in HMBPP + IL-12 or HMBPP
+ IL-2 cultures were stained with PE-anti-Vδ2 (B6, Biolegend),
and then incubated with anti-PE microbeads (Miltenyi Biotech)
to minimize potential cross-linking activation. Vδ2+ T cells
were then purified or enriched using MACS Separation columns
(Miltenyi Biotech) according manufacturer’s protocol, serving
as effector cells. The purity of enriched population is 97
± 2.2% for HMBPP + IL-12 co-cultures and 94 ± 2.06%
for HMBPP + IL-2 co-cultures assessed by flow cytometry
(Supplementary Figure 4C). Target cells (5 × 104 cells/well)
were cultured with media alone or with purified effector cells
(5 × 105 cells/well) at a ratio of E: T = 10: 1 in 96-well plates
for 3 days. Autologous B cells, which were isolated or enriched
by CD20 immunomagnetic microbeads (Miltenyi Biotech), were
included in these co-culture systems and served as negative
controls as described (15). In some special assays, 10 ug/ml of
neutralization Abs against to IFN-γ (MD-1, Biolegend), TNF-α
(MAb1, Biolegend), and IgG (MOPC-21, Biolegend) were used
to block T cell effector functions (16). Mycobacteria viability were
quantified via counting CFU as previously described (24).
Statistical Analysis
Statistical analyses of data were performed using t-test or
ANOVAmethods with Prism 6.0 (GraphPad).
RESULTS
IL-12 Family Cytokines Differently Regulate
the Expansion of HMBPP-Specific Vγ2Vδ2
T Cells
Published studies suggest that phosphoantigen HMBPP-specific
Vγ2Vδ2 T-cell subset represents fast-acting innate-like T cells,
undergoing rapid expansion and pulmonary trafficking and
residence during Mtb infection (10, 16, 28). We wondered
whether IL-12, a key innate cytokine produced by initial Mtb
infection of macrophages/DC (2, 3), plays a role in early
expansion of HMBPP-activated Vγ2Vδ2 T cells. To address
this, we examined whether IL-12 could trigger the proliferation
and expansion of Vγ2Vδ2 T cells that were stimulated with
the phosphoantigen HMBPP. The source and validation of
recombinant human IL-12 were reported in our previous study
(24). While HMBPP or IL-12 treatment alone did not induce
expansion, the combined HMBPP and IL-12 treatment (HMBPP
+ IL-12) significantly induced robust proliferation or cell
division as shown by CFSE staining (Figure 1A lower panel).
Consistently, HMBPP + IL-12 acted like HMBPP + IL-2 to
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FIGURE 1 | IL-12, but not IL-27 or IL-35, significantly drives the proliferation and expansion of HMBPP-activated Vγ2Vδ2T cells. (A) Representative flow cytometric
plots shown cellular population augmentation (upper panels) and cellular division (lower panels) of Vγ2Vδ2T cells after 7-day ex vivo co-culture with media, HMBPP
(10 ng/ml), IL-12 (25 ng/ml), or the combination of HMBPP + IL-12. Cells gated on Live cells, lymphocytes, single not doublet/triplet, and then CD3+ T cells. Vγ2Vδ2T
cells were expressed as percentage in total CD3+ T cells. Cellular division or proliferation was determined by the percentage of diluted/lower CFSE fluorescence
intensity of Vγ2Vδ2T cells. (B) Kinetics of absolute number of Vγ2Vδ2 T cells during expansion treated by HMBPP + IL-12 or HMBPP + IL-2. Data shown as mean ±
SEM of three independent experiments pooled from 12 healthy controls. (C) Both IL-27 and IL-35 failed to induce the expansion of Vγ2Vδ2T cells in PBMC followed
by HMBPP stimulation. PBMCs from healthy controls were treated by HMBPP (10 ng/ml) with or without either IL-27 or IL-35 (25 ng/ml) for 7 days. Percentages of
Vγ2Vδ2T cells in PBMC were determined by flow cytometry. The bar plot shown the percentages of Vγ2Vδ2T cells in CD3+ T cells were similar in HMBPP + IL-27 or
IL-35 vs. HMBPP only cultures. Data shown as mean ± SEM of five independent experiments pooled from 25 healthy controls. NS, not significant (p > 0.05) for
statistics. ****p < 0.0001, when HMBPP + IL-12 group is compared to media group (ANOVA, Dunnett’s test). The specific bioactivity of recombinant IL-12 cytokine
was validated in our previous publication (24) in the blockade assay using the anti-IL-12 neutralizing mAb, and this anti-IL-12 neutralizing mAb can significantly reduce
HMBPP + IL-12 expansion (not shown).
induce increases in percentage numbers of Vγ2Vδ2 T cells after
7 days of culture (Figures 1A,B).
Given that IL-12 and IL-23 are members of IL-12 cytokine
family (2, 3), and IL-23 also expands HMBPP-activated
Vγ2Vδ2 T cells (16, 19), we examined whether the other two
IL-12-family cytokines, IL-27 and IL-35, could have similar
effects on the proliferation or expansion of HMBPP-activated
Vγ2Vδ2 T cells. Surprisingly, both IL-27 and IL-35 failed
to expand HMBPP-activated Vγ2Vδ2 T cells as compared to
HMBPP treatment alone (Figure 1C). Together these results
demonstrated that like IL-23, IL-12 promoted expansion of
HMBPP-stimulated Vγ2Vδ2 T cells. These data also suggest
that cytokines in the IL-12 family mediate surprisingly diverse
functional effects on Vγ2Vδ2 T cells.
IL-12 and IL-2 Similarly Expand
HMBPP-Activated Vγ2Vδ2 T-Cell Clones,
but the IL-12-Induced Expansion Does Not
Require Endogenous IL-2 or IL-2 Signaling
Since IL-2 can strikingly expand HMBPP-activated Vγ2Vδ2 T
cells in vivo (29), we compared the IL-2 and IL-12 signals for the
expansion of HMBPP-activated γδ T cells. Here we demonstrated
that IL-12 shared with IL-2 the ability to expand Vγ2Vδ2 T
cells in the presence of HMBPP phosphoantigen, but not
anti-CD3 + anti-CD28 treatment (Supplementary Figure 1).
We then employed PCR-based cloning and sequencing to
analyze clonotypic TCR V(D)J sequences and frequencies of
expanded Vγ2Vδ2 T cells as we described earlier (25). The
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FIGURE 2 | IL-12 and IL-2 similarly expand predominant clones of HMBPP-activated Vγ2Vδ2 T cells, but the IL-12-induced expansion does not require endogenous
IL-2. (A–D) A comparison of the percentage of CDR3 length (A,B) and analysis of VDJ sequences (C,D) in Vγ2- and Vδ2-bearing TCR expressed by cells expanded
by HMBPP + IL-12 and HMBPP + IL-2, respectively. RT-PCR was used to specifically amplify the CDR3 regions of Vγ2- and Vδ2-bearing TCR cDNA.
(E) Endogenous IL-2 is not involved in IL-12 induced expansion of HMBPP-activated Vγ2Vδ2 T cells. The bar graph shows that anti-IL-2 neutralizing mAbs from two
sources (αIL-2-BD and αIL-2-RD) fail to block the ability of IL-12 to expand HMBPP-activated Vγ2Vδ2T cells (left panel), but these anti-IL-2 mAbs not isotype controls
(ISO-BD/ISO-RD) significantly reduced the IL-2 expansion of HMBPP-activated Vγ2Vδ2T cells in the HMBPP + IL-2 culture. PBMC were co-cultured with HMBPP
(10 ng/ml) plus IL-2 (5 ng/ml) or IL-12 (25 ng/ml) in the presence or absence of 5 ug/ml anti-IL-2/IL-12 antibody or isotype controls for 7 days. Data shown as mean ±
SEM of four independent experiments pooled from 20 healthy controls, ****p < 0.0001, t-test.
proof-of-concept experiment was aimed to compare IL-12 and
IL-2 expansion modes at clone levels rather than frequency
of clones. Here, we found that IL-12 and IL-2 similarly
expand predominant clones of HMBPP-activated Vγ2Vδ2 T cells
expressing the identical VDJ junctional nucleotide sequences
and CDR3 lengths (Figures 2A–D). This result suggests that
while HMBPP phosphoantigen predominantly activates selected
Vγ2Vδ2 T-cell clones, these clones can similarly be expanded
by IL-12 and IL-2 signals. Next, we investigated whether IL-
12-induced expansion of activated Vγ2Vδ2 T cells requires co-
signaling from endogenous IL-2 produced by HMBPP + IL-
12 co-culture. Our experiments indicated that IL-12-induced
expansion did not require endogenous IL-2 or IL-2 signaling
activation during HMBPP + IL-12 co-treatment, as anti-IL-
2 neutralizing antibodies from two sources failed to affect
the magnitude of the IL-12 expansion of HMBPP-activated
Vγ2Vδ2 T cells (Figure 2E). In contrast, each of these anti-
IL-2 neutralizing antibodies clearly abrogated the ability of
IL-2 to expand HMBPP-activated Vγ2Vδ2 T cells (Figure 2E).
Together, these results suggest that although IL-12 and IL-2
similarly expand HMBPP-activated Vγ2Vδ2 T cell clones, the
IL-12-induced expansion does not require endogenous IL-2 or
IL-2 co-signaling. Furthermore, we also found CD4 and CD8T
cells are not required for IL-12-induced proliferation of HMBPP-
activated Vγ2Vδ2 T cells (Supplementary Figure 2). Data also
implicate that IL-12 alone without HMBPP does not efficiently
induce Vγ2Vδ2 T cell expansion even in the presence of the
anti-CD3+ anti-CD28 stimulation.
The IL-12-Induced Expansion of
HMBPP-Activated Vγ2Vδ2T Cells Requires
Endogenous TNF-α, but Not IFN-γ
TNF-α, but not IFN-γ, has been reported to be a positive
regulator in the IL-2 induced expansion of IPP-activated
Vγ2Vδ2 T cells (30). On the other hand, our previous studies
showed that endogenous IFN-γ is critical for the IL-23-
induced expansion of HMBPP-activated Vγ2Vδ2 T cells (19, 31).
Consistent with previous data (16, 30, 32), we demonstrated
that HMBPP + IL-12 and HMBPP + IL-2 expansion of
Vγ2Vδ2 T cells led to massive production of TNF-α in the
culture supernatant, suggesting the origin of this cytokine
(Supplementary Figure 3). We therefore sought to determine
whether endogenous TNF-α and IFN-γ after HMBPP + IL-
12 co-activation were required in IL-12-induced expansion of
HMBPP-activated Vγ2Vδ2 T cells. Interestingly, blocking the
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endogenous TNF-α signal using neutralizing mAbs significantly
reduced or abrogated the ability of IL-12 to expand HMBPP-
activated Vγ2Vδ2 T cells (Figure 3A). However, the addition of
exogenous TNF-α did not significantly alter HMBPP + IL-12-
mediated expansion of Vγ2Vδ2 T cells (Figure 3B). This was
consistent with published data suggesting that TNF-α itself does
not expand Vγ2Vδ2 T cells (30). Concurrently, we found that the
IFN-γ blockade by neutralizing mAb did not reduce or abrogate
the ability of IL-12 to expand HMBPP-activated Vγ2Vδ2 T cells
(Figure 3C). Thus, these data demonstrated that TNF-α signaling
was required for optimal cell proliferation of Vγ2Vδ2 T cells.
Both PI3K/AKT and STAT4 Pathways Are
Involved in the IL-12-Induced Expansion of
HMBPP-Activated Vγ2Vδ2 T Cells
It has been shown that binding of IL-12 to the IL-12R triggers
activation of the PI3K/ATK, p38-MAPK, and JAK1/TYk2-STAT4
pathways (2, 3). This raised an interesting question as to which of
these selected signaling pathways contributes to IL-12-induced
expansion of HMBPP-activated Vγ2Vδ2 T cells. To address this,
we employed three well-documented small molecular inhibitors:
SB203580 (inhibitor for p38/MAPK), LY2944002 (inhibitor for
PI3K/AKT), and LSF (inhibitor for STAT4), respectively, in the
cultures treated with HMBPP+ IL-12 or controls. We found that
LY294002, but not SB20358, significantly reduced or inhibited the
ability of IL-12 to expand HMBPP-activated Vγ2Vδ2 T cells in a
dose-dependent manner (Figures 4A,B). Moreover, the addition
of LSF at 50µM impaired the ability of IL-12, but not IL-2,
to expand HMBPP-activated Vγ2Vδ2 T cells (Figure 4C). These
results further support a model in which IL-12 employs different
pathways from IL-2 for the growth and expansion of HMBPP-
activated Vγ2Vδ2 T cells.
Transforming growth factor-β1 (TGF-β) has been reported to
interfere with IL-12 signaling via impairing STAT4 activation and
inhibiting IL-12-induced T-cell proliferation (33). However, an
inhibitory effect of TGF-β on the IL-12 signaling activation of
HMBPP-specific Vγ2Vδ2 T cells has not been addressed. Here,
we show that the addition of exogenous TGF-β significantly
reduced or inhibited the ability of IL-12, but not IL-2, to expand
HMBPP-activated Vγ2Vδ2 T cells (Figure 4D).
Together, these results suggest that IL-12 activates the
PI3K/AKT and STAT4 signaling pathways to induce the
expansion of HMBPP-activated Vγ2Vδ2 T cells.
Vγ2Vδ2T Cells Expanded by HMBPP +
IL-12 Exhibit Central/Effector Memory
Phenotypes and Express Tissue
Trafficking Markers
Next, we sought to characterize the immune phenotypes of
Vγ2Vδ2 T cells expanded by HMBPP + IL-12 using the
cell-surface markers recently reported (34). Compared to
day 0, the majority of Vγ2Vδ2 T cells expanded at day 7
by HMBPP + IL-12 exhibited central memory (CD45RA-
CD27+) and effector memory (CD45RA-CD27-) phenotypes,
but not naïve (CD45RA+CD27+) or terminally differentiated
(CD45RA+CD27-) markers (Figures 5A,B).
We then investigated whether Vγ2Vδ2 T cells expanded in
vitro by HMBPP+ IL-12 expressed lung-tissue homing surrogate
markers like those γδ T cells increased in vivo by the IL-
2 + HMBPP administration (16). We found that most of
these Vγ2Vδ2 T cells expanded by HMBPP + IL-12 indeed
maintained the tissue-homing marker CCR5 (29) as well as LFA-
1, a surrogate for T cell-APC interactions in tissues (Figure 5C).
Taken together, these results suggest that the Vγ2Vδ2 T cells
expanded by HMBPP + IL-12 exhibit the phenotypic potentials
relevant to robust proliferation and tissue trafficking.
Vγ2Vδ2T Cells Expanded by HMBPP +
IL-12 Differentiate Into Polyfunctional
Effector Cells Expressing Antimicrobial
IFN-γ, TNF-α, GM-CSF and
Tri-CTL Molecules
It has been well documented that IL-12 helps to differentiate
antigen-stimulated CD4+ T cells into effector Th1 cells,
characterized by expression of the transcription factor T-
bet and production of IFN-γ (2, 3). Here, we compared
T-bet or Foxp3 expression on HMBPP-activated Vγ2Vδ2 T
cells following IL-12 or IL-2 treatment. The expression level
of T-bet mRNA was significantly higher in Vγ2Vδ2 T cells
expanded by HMBPP + IL-12 than those by HMBPP +
IL-2, as revealed by RT-qPCR (Figure 6A). Consistently,
Vγ2Vδ2 T cells expanded by HMBPP + IL-12 displayed a
significantly greater MFI of fluorescence-stained T-bet protein
than those γδ T cells activated by HMBPP + IL-2 (Figure 6B;
Supplementary Figure 4A). However, there was no significant
difference in Foxp3 mRNA and protein between the two groups
(Figures 6A,B; Supplementary Figure 4B).
Next, we examined the HMBPP/IL-12-driven effector
functions according to the production of specific cytokines.
Vγ2Vδ2 T cells expanded by HMBPP + IL-12 were assessed for
the ability to produce anti-microbial cytokines using intracellular
cytokine staining (ICS) after HMBPP re-stimulation. We
focused on IFN-γ, TNF-α, GM-CSF, or CD107a, as they were all
necessary for anti-TB effector function or CTL function (14, 16).
The results for production and co-production of these cytokines
are summarized in 15 individual and combinational displays
in Figure 6C and Supplementary Figures 5A–B. Overall, co-
culture with HMBPP + IL-12 resulted in higher frequencies of
Vγ2Vδ2 T effector cells producing IFN-γ or TNF-α than did
HMBPP + IL-2 (Figure 6C; Supplementary Figure 5). Notably,
Vγ2Vδ2 T cells expanded by HMBPP+ IL-12 displayed a higher
frequency of poly-effector functional T cells co-producing IFN-γ
and TNF-α and CD107a or these 3 plus GM-CSF than did those
by HMBPP + IL-2(Figure 6C; Supplementary Figure 5). These
polyfunctional Vγ2Vδ2 T effector cells have been implicated as a
surrogate marker for a protective anti-TB immune response (31).
It has recently been shown that CD8+ tri-cytotoxic T cells
producing Granzyme B, granulysin, and perforin (Tri-CTL)
exhibit a stronger ability to kill intracellular Mtb than those
CTL producing only one or two of these three cytokines (35).
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FIGURE 3 | The IL-12-induced expansion of HMBPP-activated Vγ2Vδ2 T cells requires endogenous TNF-α, but not IFN-γ. Pooled graph data of the percentage of
Vγ2Vδ2T cells in CD3+ T cells expanded after the 7-day in the PBMC culture treated with HMBPP + IL-12 in the presence or absence of 10 ug/ml
cytokine-neutralizing antibodies of anti-IFN-γ (A) or anti-TNF-α mAb (C). Data are mean ± SEM of three independent experiments pooled from 12 healthy controls
****p < 0.0001, paired t-test. (B) Exogenous TNF-α did not enhance the ability of IL-12 to expand HMBPP-activated Vγ2Vδ2T cells. TNF-α (25 or 50 ng/ml) was
added to HMBPP + IL-12 cultures, and cells were cultured for 7 days prior to measuring expansion of Vγ2Vδ2T cells. Data shown as mean ± SEM of three
independent experiments pooled from 12 healthy controls.
FIGURE 4 | Both PI3K/AKT and STAT4 pathways, but not p38/MAPK, are involved in the IL-12-induced expansion of HMBPP-activated Vγ2Vδ2 T cells. (A–C) are
graph data showing that PI3K/AKT and STAT4, but not P38/MAPK pathway, were required for HMBPP + IL-12 expansion of Vγ2Vδ2 T cells was reduced by the
chemical blockers for PI3K/AKT and STAT4 pathways, but not those for P38/MAPK. PBMCs were co-cultured for 7 days with HMBPP + IL-2 or HMBPP + IL-12 in
the presence of escalating doses (1, 5, 10µM) of LY2944002 (inhibitor for PI3K/AKT), SB203580 (inhibitor for p38/MAPK), or doses (10, 20, 30, 40, 50µM) of LSF
(inhibitor for STAT4) or DMSO. Data are mean ± SEM of three independent experiments pooled from 12 healthy controls. **p < 0.01, vs. media group (ANOVA,
Dunnett’s test). (D) Exogenous TGF-β significantly reduce the ability of IL-12, but not IL-2, to expand HMBPP-activated Vγ2Vδ2 T cells. TGF-β (10 or 100 ng/ml) was
added to the PBMC cultures treated with HMBPP + IL-12 or HMBPP + IL-2 (n = 12), and cells were cultured for 7 days prior to the flow-based analysis of the
expansion of Vγ2Vδ2T cells. Each dot represents one healthy control. **p < 0.01 vs. control group (paired t-test).
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FIGURE 5 | Vγ2Vδ2T cells expanded by HMBPP + IL-12 exhibit central/effector memory phenotypes and maintain tissue trafficking markers. (A) Shown in the left
are representative flow-cytometry quadrats displaying memory surrogate markers of Vγ2Vδ2T cells based on CD27 and CD45RA expression in HMBPP + IL-12
cultures at day 0 and 7. Data at day 0 are similar to those in the medium only control culture. Shown in the right are representative flow cytometry histograms
uncovering the phenotype of the αβ T cells that are cultured and gated in cytometry similarly to Vγ2Vδ2T cells. (B) Bar graph shows that Vγ2Vδ2T cells expanded by
HMBPP + IL-12 express effector and central memory phenotypes. (C) Flow histogram and graph data show that expanded Vγ2+Vδ2+ T cells maintain expression of
tissue-trafficking/residence markers CCR5 and LAF-1. Flowcytometry data are gated on live individual lymphocytes, CD3+, then Vγ2Vδ2+, and then representative
markers. Data shown are mean ± SEM of three independent experiments pooled from 15 healthy controls.
We therefore assessed Vγ2Vδ2 T cells expanded by HMBPP
+ IL-12 for the expression of these CTL granule molecules
which contribute to killing of intracellular pathogens (14–
16, 36). We found that HMBPP re-stimulation significantly
up-regulated expression of the tri-CTL molecules as well as
GZMA (Figure 6D).
Vγ2Vδ2T Cells Expanded by HMBPP +
IL-12 Inhibit the Growth of Intracellular
Mycobacteria in an IFN-γ- or
TNF-α-Dependent Fashion
Given that Vγ2Vδ2 T cells expanded by HMBPP + IL-12
expressed multiple anti-mycobacterial cytokines, we tested a
possibility that these expanded cells could directly restrict
intracellular mycobacteria growth. We performed a proof-of-
concept experiment using BCG-infected targets, as Vγ2Vδ2 T
effector cells capable of restricting intracellular BCG replication
can also similarly inhibit intracellular Mtb growth (14–16). Since
our earlier studies showed that activated Vγ2Vδ2 T effector
cells more strikingly inhibited Mtb growth than resting γδ T
cells (15, 16), here we comparatively evaluated IL-12- and IL-
2-activated Vγ2Vδ2 T effector cells for BCG growth inhibition.
Thus, expanded Vγ2Vδ2 T effector cells were co-cultured
with BCG-infected THP-1 or autologous human monocyte-
derived macrophages (hMDM) and then assessed for their
ability to influence intracellular BCG growth. We found that
Vγ2Vδ2 T effector cells purified from HMBPP + IL-12 cultures
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FIGURE 6 | Vγ2Vδ2T cells expanded by HMBPP + IL-12 differentiate into polyfunctional effector cells expressing antimicrobial IFN-γ, TNF-α, GM-CSF, and tri-CTL
cytokines. (A) Vγ2Vδ2T cells expanded by HMBPP + IL-12 expressed higher level of TBX21 than those expanded by HMBPP/IL-2. PBMC were cultured with
HMBPP + IL-12 (white bars) or HMBPP + IL-2 (black bars) for 7 days, and expanded Vγ2Vδ2T cells were purified. Then, enriched Vγ2Vδ2T cells were used for RNA
isolation and determination of the expression levels of TBX21 and FOXP3. Cells from HMBPP + IL-2 treatment served as control setting. Shown are mean ± SEM of
three independent experiments pooled from 15 healthy controls, ****p < 0.0001, t-test. (B) Pooled flow-cytometry data (12 healthy controls) show the frequencies of
T-bet+ cells (left) and mean fluorescence index (MFI) expression of Foxp3 (right) in gated Vγ2Vδ2T cells expanded by HMBPP + IL-12 or HMBPP + IL-2. Each dot
represents one healthy control. ***p < 0.001, paired t-test. (C) Percentage numbers of Vγ2Vδ2 T cells expanded by HMBPP + IL-12 or HMBPP + IL-2 could produce
CD107a, IFN-γ, TNF-α, and GM-CSF in 15 combinations in response to HMBPP stimulation. Using Boolean analysis, the bar graph shows percentages of individual
multi-functional effector subsets for Vγ2Vδ2T cells expanded by HMBPP + IL-12 (white bars) and HMBPP + IL-2 (black bars). Gating was on individual live
lymphocytes, CD3+ T, then Vγ2+Vδ2+ T cells and then those cytokine markers. Shown are mean ± SEM of three independent experiments pooled from 15 healthy
controls, ****p < 0.0001, ***p < 0.001, t-test. (D) Bar graph shows fold changes in expression levels of GZMA, GZMB, GNLY, and PRF in HMBPP + IL-12-expanded
Vγ2Vδ2T cells after HMBPP or media stimulation. Data are from four independent experiments pooled from 15 healthy controls. ****p < 0.0001, ***p < 0.001, **p <
0.01, t-test. Representative flow cytometric histograms are in Supplementary Figure 5A.
(Supplementary Figure 4C) significantly inhibited BCG growth
in THP-1 and autologous hMDM target cells, compared to
the controls autologous B cells or media alone (Figure 7A).
These results were consistent with the previous observation that
Vγ2Vδ2 T effector cells generated in vivo during infection or
phosphantigen + IL-2 administration could limit intracellular
Mtb or Listeria monocytogenes growth (15, 16, 37, 38). Finally,
we performed mechanistic experiments to examine whether
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FIGURE 7 | Vγ2Vδ2T cells expanded by HMBPP + IL-12 inhibit intracellular mycobacteria growth in IFN-γ- and TNF-α-dependent fashions. (A) HMBPP +
IL-12-expanded Vγ2Vδ2T cells inhibit intracellular BCG growth in THP-1 and hMDM cells, respectively. Vγ2Vδ2T cells enriched from HMBPP + IL-12 or HMBB + IL-2
co-cultures by positive selection (see Supplementary Figure 1D for the purity) were co-cultured with BCG-infected THP-1 (left panel) or hMDM (right panel) cells at
an E: T ratio = 10:1 for 72 h. The reduction of CFU counts induced by Vγ2Vδ2T cells was significantly more striking than that by B cells or media only. (B) Blocking
assays using neutralizing mAb show that Vγ2Vδ2 T cells enriched from HMBPP + IL-12 cultures require effector molecules, IFN-γ and TNF-α, to inhibit intracellular
mycobacteria. Vγ2Vδ2T cells enriched from HMBPP + IL-12 cultures were incubated with BCG-infected THP-1 and hMDM cells at an E: T ratio of 10: 1 for 3 days in
the presence/absence of 10 ug/ml neutralizing antibodies against IFN-γ, TNF-α, or matched Isotype. Data are mean ± SEM of three independent experiments pooled
from 15 healthy controls, ****p < 0.0001, ***p < 0.001 vs. control (ANOVA, Dunnett’s test).
endogenous IFN-γ or TNF-α contributed to the ability of
HMBPP+ IL12-expanded Vγ2Vδ2 T cells to inhibit intracellular
mycobacterial growth. Interestingly, both anti-IFN-γ and anti-
TNF-α neutralizing mAbs significantly reduced or abrogated the
ability of expanded Vγ2Vδ2 T cells to inhibit BCG growth in
THP-1 and hMDM cells (Figure 7B). Thus, these results support
the view that Vγ2Vδ2 T cells expanded by HMBPP + IL-12
inhibit intracellular mycobacteria growth in an IFN-γ- and TNF-
α-dependent fashions.
DISCUSSION
To our knowledge, the current study provides new evidence that
IL-12 helps to promote expansion and differentiation of HMBPP-
activated Vγ2Vδ2 T cells through signaling activities involving
PI3K/AKT and STAT4 and TNF-α pathways, but not p38/MAPK,
IL-2, IFN-γ networks. Vγ2Vδ2 T cells expanded by HMBPP
+ IL-12 display a memory phenotype of rapid proliferation,
produce/co-produce anti-microbial cytokines IFN-γ, TNF-α,
GM-CSF, and CD107a, express the Mtb-killing tri-CTL cytotoxic
granule molecules GZMB, GNLY, and PRF. Importantly, these
expanded Vγ2Vδ2 T cells can inhibit intracellular BCG growth
in autologous hMDM and THP-1 cells. These findings support
the hypothesis that IL-12, a key innate cytokine produced by
initial Mtb infection, helps to drive early development of fast-
acting Vγ2Vδ2 T effector cells in anti-TB immune responses
(10, 15, 16, 28).
The IL-12 effects on Vγ2Vδ2 T cells have been evaluated
in vitro in humans with HIV-1 infection (32, 39) and cancer
(40). IL-12 helps to produce IFN-γ/TNF-α in the responder
subset of HIV-1-infected humans, but fails to induce the
activation of Vγ2Vδ2 T cells from anergic HIV-infected persons
(32). While IL-12 and IL-18 synergize Vγ2Vδ2 T cell-mediated
cytotoxicity against tumor cells (23), IL-18 enhances the
proliferative and recall response of Vγ2Vδ2 T cells from HIV-
1-infected individuals (39). Here, we extend the published
studies to demonstrate that the defined IL-12 signaling
expands and differentiates human Vγ2Vδ2 T effector cells
producing antimicrobial cytokines and inhibiting intracellular
mycobacterial growth.
IL-12 family cytokines include IL-12, IL-23, IL-27, and IL-35
and have specific roles in the initiation, expansion, and control of
immune responses of αβ CD4+ T cells in Mtb infection (41). Our
current and earlier studies demonstrate that only IL-12 and IL-
23 in the IL-12 family can induce robust proliferation/expansion
and functional differentiation of HMBPP-activated Vγ2Vδ2 T
cells (16, 19). It is noteworthy that absence or mutation of IL-
12p40 or the IL-12Rβ1 (the shared component for the IL-12
and IL-23 receptor) correlate well with the incidence of TB
(42, 43). The genetic defects in humans may impact potential
anti-TB immunity involving both CD4+ Th1/Th17 and major
Vγ2Vδ2 T-cell subsets. IL-12 and IL-23 promote protective anti-
TB CD4+ Th1 and Th17 cells, respectively (44), and expand and
differentiate HMBPP-specific Vγ2Vδ2 T cells. HMBPP-specific
Vγ2Vδ2 T cells exist only in humans and NHP, constitute
65–90% of total circulating human γδ T cells. Recent NHP
studies using in vivo HMBPP + IL-2 expansion of Vγ2Vδ2 T
cells and adoptive transfer of Vγ2Vδ2 T cells demonstrate that
Vγ2Vδ2 T effector cells can protect against high-dose Mtb
infection (15, 16).
Our data implicate signaling requirements or functional
mechanisms for the IL-12-induced expansion/differentiation
of HMBPP-activated Vγ2Vδ2 T cells. The IL-12 expansion of
Vγ2Vδ2 T cells requires signaling via STAT4 and PI3K/AKT,
but not p38/MAPK. This is in line with the published
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observation that PI3K/AKT pathway is required for IL-12-
induced Th1 maturation of CD4+ T cells (45). The data
of IL-12 signaling requirements strongly suggest that IL-
12 directly expands HMBPP-activated Vγ2Vδ2 T cells, rather
than an indirect consequence. This notion is also supported
by the fact that IL-12 acts like IL-2 to selectively expand
Vγ2Vδ2 T cells activated by HMBPP, but not by anti-
CD3+anti-CD28 stimulation. Nevertheless, the IL-12-STAT4
and PI3K/AKT pathways are quite different from the IL-2
signaling pathway or mechanisms (20, 21). Consistently, IL-
12-induced expansion of HMBPP-activated Vγ2Vδ2 T cells is
independent upon endogenous IL-2 or IL-2 signaling, although
IL-2 and IL-12 share the ability to expand predominant
clones of HMBPP-selected γδ T cells. This is also different
from the IL-23-mediated expansion of Vγ2Vδ2 T cells, which
involves endogenous IL-2 (16). Interestingly, endogenous TNF-
α signaling is involved in both IL-12 and IL-2 signaling
expansion of HMBPP-activated Vγ2Vδ2 T cells. These findings
suggest that TNF-α signaling contributes to IL-2 and IL-12
expansion of multiple anti-TB T effector subsets including
CD4+Th1, CD8+CTL, the predominant Vγ2Vδ2 T subset and
NKT cells. These TNF-α cytokine networks help explain
further the observation that anti-TNFα mAb treatment in RA
patients with LTBI leads to dysfunction of CD8+ T cells
or other T effectors, with consequence of reactivation of
tuberculosis (46).
The current study also identifies the antagonistic cytokine
negatively regulating the IL-12-induced expansion of HMBPP-
activated Vγ2Vδ2 T cells. Specifically, we find that TGF-β can
negatively regulate the HMBPP + IL-12 expansion of Vγ2Vδ2 T
cells. Virtually, TGF-β has been found to significantly inhibit
the IL-12–induced phosphorylation of the STAT4, leading to
a decrease in IL-12–induced STAT4 binding to DNA and
subsequent inactivation of αβ T cells (33). The increased
production and activity of TGF-β in TB patients (47) may
help to explain dysfunction of TB-specific Vγ2Vδ2 T effector
cells (31).
Vγ2Vδ2 T effector cells expanded by HMBPP + IL-
12 exhibit central/effector memory and tissue trafficking
phenotypes of robust proliferation potential. ∼60% of these
Vγ2Vδ2 T cells express the CD45RA-CD27+ central memory
phenotype linked to cytokine production (48), and ∼40% of
them displayed the effector memory phenotype, which are
depleted in active TB and TB/HIV-1 coinfection (49). Our
recent adoptive transfer study demonstrates that Vγ2Vδ2 T
effector cells with such phenotypes can rapidly traffic to and
accumulate in pulmonary compartment and protect against
high-dose Mtb infection in NHP (16). Similar phenotypes
and anti-TB immunity are also seen during cHMBPP + IL-
2 administration as immune manipulation of Mtb-infected
macaques (15).
Our data show that HMBPP + IL-12 coactivation
differentiates and enables Vγ2Vδ2 T cells to acquire the
pleiotropic capability to produce multiple anti-TB cytokines that
can inhibit or kill intracellular Mtb bacilli (14–16). Particularly,
Vγ2Vδ2 T cells expanded by HMBPP + IL-12 can produce and
co-produce IFN-γ and TNF-α and GM-CSF. In this context,
these γδ T effector cells express Mtb-killing tri-CTL granule
molecules GZMB, GNLY and PRF. It is important to note that
IFN-γ and TNF-α and GM-CSF are well-defined cytokines
capable of inhibiting Mtb growth and that CD8+ tri-CTL
expressing GZMB, GNLY, and PRF are the CTL subset that can
kill intracellular Mtb more efficiently than others (35).
Consistent with the anti-TB cytokine profiles, Vγ2Vδ2 T
cells expanded by HMBPP + IL-12 can efficiently inhibit
intracellular BCG growth in human THP-1 macrophages
and autologous hMDM. The mechanism by which Vγ2Vδ2 T
cells expanded by HMBPP + IL-12 inhibit intracellular
BCG growth appears to involve IFN-γ and TNF-α as shown
by cytokine-blocking experiments. This is consistent with
previous data indicating that TNF-α and IFN-γ, as well as
PRF, GNLY, and granzyme A inhibit intracellular Mtb growth
(14–17, 36). Although the current study does not test the
inhibition of Mtb growth, earlier studies demonstrate that
Vγ2Vδ2 T effector cells capable of restricting intracellular
BCG replication can also similarly inhibit intracellular Mtb
growth (14, 16). It is also noteworthy that we focused on
IL-12- expanded Vγ2Vδ2 T effector cells, as resting un-
activated Vγ2Vδ2 T cells would not efficiently produce
those anti-TB cytokines or potently inhibit mycobacterial
growth (14, 16).
Thus, the current study provides new information
demonstrating that IL-12 augments the proliferation and
expansion of HMBPP-activated Vγ2Vδ2 T cells. Data implicate
cytokine signaling networks in which IL-12 enables Vγ2Vδ2 T
cells to differentiate to polyfunctional effector cells producing
multiple anti-TB cytokines and inhibiting mycobacterial
growth. Findings support the hypothesis that IL-12, a key
innate cytokine produced by initial Mtb infection, may help
to drive early development of fast-acting Vγ2Vδ2 T cells
in anti-TB immune responses (10, 16, 28). Given that IL-
12 and IL-2 similarly expand HMBPP-activated Vγ2Vδ2
T-cell clones but act via distinct mechanisms (20, 21),
targetting these two powerful cytokines may provide a
strategy to enhance antimicrobial Vγ2Vδ2 T cells responses
to intervene in patients with multi-drug resistant and/or
disseminated tuberculosis.
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